Keratinocyte proline‐rich protein modulates immune and epidermal response in imiquimod‐induced psoriatic skin inflammation
Experimental Dermatology · 2023
DOI: 10.1111/exd.14960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Ai Matsuno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Psoriasis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by ROHTO Pharmaceutical Co., Ltd., JSPS KAKENHI Grant Number 20K08647 (to HS) from the Japan Society for the Promotion of Science, and….
Abstract (Originalsprache)
Psoriasis is a persistent inflammatory skin disease thought to arise as a result of the infiltration of inflammatory cells and activation of keratinocytes. Recent advances in basic research and clinical experience revealed that the interleukin (IL)‐23/IL‐17 axis has been identified as a major immune pathway in psoriasis. However, it remains unclear how keratinocyte factors contribute to the pathology of psoriasis. Keratinocyte proline‐rich protein (KPRP) is a proline‐rich insoluble protein, which is present in the epidermis and is likely to be involved in the skin barrier function. Here, to investigate the potential roles of KPRP in psoriatic skin inflammation, Kprp ‐modified mice were applied in the imiquimod (IMQ)‐induced skin inflammation model, which develops psoriasis‐like epidermal hyperplasia and cutaneous inflammation features. Then, heterozygous knockout ( Kprp +/− ) but not homozygous knockout ( Kprp −/− ) mice displayed attenuated skin erythema compared to control wild‐type mice. In addition, RNA sequencing, quantitative PCR and/or histological analysis detected changes in the expression of several molecules related to psoriatic inflammation or keratinocyte differentiation in Kprp +/− mice, but not Kprp −/− mice. Further analysis exhibited reduced IL‐17‐producing γδ low T cells and amplified epidermal hyperplasia in Kprp +/− mice, which were implied to be related to decreased expression of β‐defensins and increased expression of LPAR1 (Lysophosphatidic acid receptor 1), respectively. Thus, our results imply that KPRP has the potential as a therapeutic target in psoriatic skin inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Scleroderma Center, The University of Tokyo Hospital, Tokyo, Japan.
- SLE Center, The University of Tokyo Hospital, Tokyo, Japan.
- Research and Development Division, Rohto Pharmaceutical Company, Osaka, Japan.
- Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Hayakazu Sumida, Hirofumi Nakanishi
Förderung
- This study was supported by ROHTO Pharmaceutical Co., Ltd., JSPS KAKENHI Grant Number 20K08647 (to HS) from the Japan Society for the Promotion of Science, and…
Zitieren
APA
Matsuno, A., Sumida, H., Nakanishi, H., Ikeyama, Y., Ishii, T., Omori, I., Saito, H., Iwasawa, O., Sugimori, A., Yoshizaki, A., Katoh, H., Ishikawa, S., & Sato, S. (2023). Keratinocyte proline‐rich protein modulates immune and epidermal response in imiquimod‐induced psoriatic skin inflammation. Experimental Dermatology. https://doi.org/10.1111/exd.14960
Vancouver
Matsuno A, Sumida H, Nakanishi H, Ikeyama Y, Ishii T, Omori I, et al. Keratinocyte proline‐rich protein modulates immune and epidermal response in imiquimod‐induced psoriatic skin inflammation. Experimental Dermatology. 2023. doi:10.1111/exd.14960
BibTeX
@article{Matsuno2023,
author = {Matsuno, Ai and Sumida, Hayakazu and Nakanishi, Hirofumi and Ikeyama, Yoshifumi and Ishii, Tsuyoshi and Omori, Issei and Saito, Hinako and Iwasawa, Okuto and Sugimori, Ayaka and Yoshizaki, Ayumi and Katoh, Hiroto and Ishikawa, Shumpei and Sato, Shinichi},
title = {Keratinocyte proline‐rich protein modulates immune and epidermal response in imiquimod‐induced psoriatic skin inflammation},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14960}
}
EUVIMED